Change of Director's Interest Notice
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Mayne Pharma Group Limited
ABN 76 115 832 963
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Shawn Patrick O’Brien
Date of last notice 06 December 2024
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest Direct and Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Solium Nominees (Australia) Pty Ltd as
custodian for the Mayne Pharma Group
Performance Rights and Option Plan (the
‘Plan’)
Date of change 16-18 December 2025
No. of securities held prior to change Direct:
35,170 RSU Performance Rights
932,296 Performance Rights
37,041 Ordinary Shares
Indirect:
23,816 Ordinary Shares held by Solium
Nominees (Australia) Pty Ltd as custodian for
the Mayne Pharma Group Performance
Rights and Option Plan (the ‘Plan’)
Class Ordinary Shares
Number acquired 326,452 Ordinary Shares
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Number disposed 35,170 RSU Performance Rights (as a result
of the exercise of RSU Performance Rights)
364,103 Performance Rights (291,282
exercised and 72,821 forfeited as they did
not meet the vesting conditions)
129,736 Ordinary Shares disposed following
the exercise of Performance Rights, sold to
cover tax obligations.
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
Nil consideration for exercise of
Performance Rights and RSU Performance
Rights.
$401,341.04 received for Ordinary Shares
sold to cover tax obligations.
No. of securities held after change Direct:
Nil RSU Performance Rights
568,193 Performance Rights
37,041 Ordinary Shares
Indirect:
220,532 Ordinary Shares held by Solium
Nominees (Australia) Pty Ltd as custodian for
the Mayne Pharma Group Performance
Rights and Option Plan (the ‘Plan’)
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Exercise of Performance Rights and RSU
Performance Rights pursuant to the Plan
On market sale of Ordinary Shares.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the trade
to proceed during this period?
Not applicable
If prior written clearance was provided, on what date was this
provided?
Not applicable
Share your feedback
Discover